CoinInsight360.com logo CoinInsight360.com logo
America's Social Casino

crypto.news 2025-06-18 05:31:45

Nasdaq-listed firm announces $50M Hyperliquid reserve — will HYPE rise further?

A Nasdaq-listed biotech company is betting big on crypto with a $50 million move into Hyperliquid’s HYPE token. According to a June 17 press release from Eyenovia, Inc., a U.S.-based ophthalmic technology firm, the company has secured $50 million in private equity financing to accumulate over 1 million Hyperliquid ( HYPE ) tokens. With this move, Eyenovia becomes the first publicly traded U.S. company to hold HYPE in its treasury and operate as a Hyperliquid blockchain validator. The funding deal includes convertible preferred shares and warrants, which could raise up to $150 million if fully exercised. Alongside the announcement, Eyenovia named Hyunsu Jung as chief investment officer and board member to oversee the new digital asset strategy. “We’re pleased to join the growing number of companies adopting cryptocurrency treasury strategies,” said chief executive officer Michael Rowe. “We believe this move supports long-term capital appreciation and shareholder value.” You might also like: Can Hyperliquid rise to $50 in June? Jung called HYPE “the most robust digital asset,” citing Hyperliquid’s rapid growth and leading onchain revenue. HYPE ranks as the 12th-largest cryptocurrency by market cap, having surged 380% from its April low to an all-time high of $45.57 on June 16. At press time, HYPE is trading at $40.24, down 11% from its peak. Hyperliquid, a high-speed Layer 1 blockchain optimized for perpetuals trading, has seen a wave of adoption. In the past 30 days, it has accounted for 60% of the total onchain perps volume, according to data from a Dune Analytics dashboard. Monthly perps volume has topped $250 billion, making it a strong competitor to centralized exchanges such as Binance. Eyenovia plans to execute a staking strategy with its HYPE holdings and use Anchorage Digital to secure its assets. In addition, the company will rebrand to “Hyperion DeFi” and change its ticker symbol to HYPD. Eyenovia will keep working on its flagship Optejet eye treatment device, which is expected to receive FDA registration by September, while branching out into cryptocurrency. If other public companies follow Eyenovia’s lead, Hyperliquid could see a sharp increase in token demand and network effects, potentially positioning it as a top 10 blockchain by market capitalization. Read more: No VC, $1B Trades, and a 300% Rally — what makes Hyperliquid crypto tick?

면책 조항 읽기 : 본 웹 사이트, 하이퍼 링크 사이트, 관련 응용 프로그램, 포럼, 블로그, 소셜 미디어 계정 및 기타 플랫폼 (이하 "사이트")에 제공된 모든 콘텐츠는 제 3 자 출처에서 구입 한 일반적인 정보 용입니다. 우리는 정확성과 업데이트 성을 포함하여 우리의 콘텐츠와 관련하여 어떠한 종류의 보증도하지 않습니다. 우리가 제공하는 컨텐츠의 어떤 부분도 금융 조언, 법률 자문 또는 기타 용도에 대한 귀하의 특정 신뢰를위한 다른 형태의 조언을 구성하지 않습니다. 당사 콘텐츠의 사용 또는 의존은 전적으로 귀하의 책임과 재량에 달려 있습니다. 당신은 그들에게 의존하기 전에 우리 자신의 연구를 수행하고, 검토하고, 분석하고, 검증해야합니다. 거래는 큰 손실로 이어질 수있는 매우 위험한 활동이므로 결정을 내리기 전에 재무 고문에게 문의하십시오. 본 사이트의 어떠한 콘텐츠도 모집 또는 제공을 목적으로하지 않습니다.